NCT07644312
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG
Not Yet Recruiting · Phase 2 · Nationwide Children's Hospital · registry updated 2026-09-09
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.
Inclusion
- Patients must be ≥12 years and ≤39 years of age at the time of enrollment on TarGeT-SCR.
- Within the United States, patients must weight ≥ 40 kg at the time of enrollment. For all other countries, patients must weight ≥ 30 kg at the time of enrollment.
- Patients with newly-diagnosed HGG, including DIPG, are eligible. All patients mut have histologic confirmation from diagnostic biopsy or resection. The diagnosis of HGG, including DIPG must have been confirmed through TarGeT-SCR.
- All HGGs must be WHO Grade 3 or 4. Note: WHO Grade 2 gliomas with pontine epicenter and diffuse involvement of at least 2/3 of the pons are eligible.
- Disease Status:
- Patients must be newly diagnosed.
Exclusion
- Pregnant or breastfeeding patients are excluded.
- Patients with uncontrolled infection.
- Patients with bone marrow failure syndrome.
- Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
- Inflammatory bowel disease
- Moderate to severe pulmonary conditions defined by need for medical intervention and/or limiting activities of daily living or shortness of breath with limited exertion.